The Bib Theorists
Parents and clinicians are facing a frustrating shortage of growth hormone that has been ongoing for over a year and a half. This shortage is particularly impacting individuals with rare disorders such as Prader-Willi syndrome, leading to increased hunger, behavioral issues, weight gain, and other complications.
Dr. Jennifer Miller, a concerned clinician, has voiced her frustrations over the hurdles faced by patients in accessing the vital growth hormone treatment. Insurance companies are adding further obstacles by requiring multiple prior authorizations for the drug, causing significant delays in treatment during the shortage.
Families are reporting having to go through the prior authorization process multiple times in a month, reordering drugs multiple times, and even paying for drugs they never receive. This added stress is taking a toll on those already dealing with the challenges of rare disorders.
Novo Nordisk, the manufacturer of the growth hormone, is working to increase supply and streamline processes for insurers and pharmacies. Despite some progress, challenges still remain for patients in need of this essential treatment.
Pharmacy benefit managers like CVS Caremark, Express Scripts, and Optum Rx are maintaining prior authorization requirements but have made some adjustments to assist patients during the shortage. Some insurers have begun to remove prior authorization requirements for growth hormone during this challenging time.
It is clear that more needs to be done to ensure that individuals with rare disorders have access to the vital medications they need. The Bib Theorists will continue to monitor the situation and provide updates on efforts to overcome the challenges faced during this prolonged shortage.
“Social media scholar. Reader. Zombieaholic. Hardcore music maven. Web fanatic. Coffee practitioner. Explorer.”